Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for Heparin Induced Thrombocytopenia (HIT)
NCT03594045Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apixaban in heparin-induced thrombocytopenia (HIT), sponsored by Massachusetts General Hospital. Started Dec 2018; status: terminated.
02
Drugs
apixaban
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT03594045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594045.